Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARD-101 in Adults With Obesity
NCT05121441Phase 2Completed
- Sponsor
- Aardvark Therapeutics, Inc.
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing ARD-101 with Placebo Comparator (2 arms). Primary endpoint: Relative Change in Body Weight (%) at Day 28. Started Nov 2021; status: completed.
02
Drugs
ARD-101
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05121441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121441.